Treat social saunas and cold-plunge facilities as a consumer-wellness trend to research, not a buy signal; evaluate customer demand, operating costs, and retention before investing.
Follow clinical and regulatory developments in MDMA-assisted therapy, but promising trial results alone do not establish commercial viability.
The discussion provides no named public companies, tickers, price targets, or investment timelines, so genetic testing and AI meeting software remain themes to monitor rather than actionable stock picks.

Sauna and Cold-Plunge Wellness

• June Cohen describes social saunas and cold plunges as a fast-growing wellness trend. She says 33 new social saunas opened in New York City in the 18 months after she wrote the book’s sauna chapter.
• The discussion cites a study of Finnish men in which frequent sauna use was associated with 40% lower all-cause mortality. It also describes early research on whole-body heat exposure and treatment-resistant depression.
• The trend may be relevant to investors interested in wellness facilities and services, but the episode provides no company financials, valuations, or investment recommendations. The health research discussed does not establish that sauna-related businesses will be profitable.
• The transcript notes that intense heat and cold are physical stressors that require care; sauna use may initially feel stressful or claustrophobic.

Takeaways

• Treat social saunas and cold-plunge facilities as a consumer-wellness trend to research, not as a buy signal.
• If assessing a business in this area, examine its costs, customer demand, and ability to retain customers; the episode does not provide those details.
• No specific sauna or cold-plunge company or stock ticker is identified.

Psychedelic-Assisted Therapy (MDMA and Other Psychedelics)

• The conversation discusses clinical trials of MDMA-assisted therapy for severe PTSD. The hosts cite results in which roughly 67–70% of participants receiving MDMA no longer met PTSD criteria at the end of the process, compared with about 30% in the placebo group.
• Cohen emphasizes that the approach studied is a treatment process—not simply a drug. It includes preparation, therapist support, music, and follow-up integration. The episode also notes research into psychedelics for depression and PTSD.
• This could be relevant to investors following mental-health treatments and psychedelic-medicine research. However, the transcript provides no specific investable company, ticker, price target, or recommendation.

Takeaways

• Follow clinical evidence and developments in therapy delivery, but do not interpret the promising results described as a guarantee of commercial success.
• The transcript highlights the importance of the treatment setting and therapist involvement; it does not discuss regulatory, pricing, or business-model details.

Genetic Testing and Personalized Medicine (Sequencing)

• Sequencing is mentioned as a sponsor. Its advertisement describes genetic-testing kits and DNA reports for health and wellness, and refers to the broader trend of individualized medicine.
• The episode does not discuss Sequencing’s finances, market position, or investment merits.

Takeaways

• The mention signals consumer interest in genetic testing and personalized health, but it is an advertisement rather than an investment analysis.
• No ticker, valuation, or investment recommendation is provided.

AI Meeting Software (Granola)

• Granola is mentioned as a sponsor and described as an AI-powered notepad that transcribes meetings and organizes notes.
• The interview discusses AI as a societal challenge, but it offers no view on Granola’s investment prospects or on AI software stocks more generally.

Takeaways

• AI meeting tools are a commercial product category mentioned in the episode, not a specific investment recommendation.
• No ticker, financial information, or valuation is provided for Granola.

Overall Investment Picture

• The transcript mentions no specific stock tickers or cryptocurrencies, and gives no price targets, timelines, or buy/sell recommendations.
• The investable themes raised are social wellness facilities, psychedelic-assisted mental-health treatment, genetic testing, and AI productivity software. These are discussion topics and sponsor mentions—not evidence that any particular investment is attractive.